Amgen (NASDAQ: AMGN) will present data from its Phase 3 VESALIUS-CV clinical trial of Repatha at the American Heart Association ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE